Literature DB >> 18615107

Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR.

O Pelz-Ackermann, M Cross, H Pfeifer, M Deininger, S-Y Wang, H K Al-Ali, D Niederwieser, T Lange.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18615107     DOI： 10.1038/leu.2008.180

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

Review 1.  Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.

Authors:  Alicia J Angelbello; Jonathan L Chen; Jessica L Childs-Disney; Peiyuan Zhang; Zi-Fu Wang; Matthew D Disney
Journal:  Chem Rev       Date:  2018-01-11       Impact factor: 60.622

2.  A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.

Authors:  Thomas Ernst; Franz X Gruber; Oliver Pelz-Ackermann; Jacqueline Maier; Markus Pfirrmann; Martin C Müller; Ingvild Mikkola; Kimmo Porkka; Dietger Niederwieser; Andreas Hochhaus; Thoralf Lange
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

3.  Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?

Authors:  Simona Soverini; Gianantonio Rosti; Ilaria Iacobucci; Michele Baccarani; Giovanni Martinelli
Journal:  Oncologist       Date:  2011-05-31

4.  The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia.

Authors:  Thoralf Lange; Thomas Ernst; Franz X Gruber; Jacqueline Maier; Michael Cross; Martin C Müller; Dietger Niederwieser; Andreas Hochhaus; Markus Pfirrmann
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

5.  Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.

Authors:  Simona Soverini; Caterina De Benedittis; Katerina Machova Polakova; Jana Linhartova; Fausto Castagnetti; Gabriele Gugliotta; Cristina Papayannidis; Manuela Mancini; Hana Klamova; Marzia Salvucci; Monica Crugnola; Alessandra Iurlo; Francesco Albano; Domenico Russo; Gianantonio Rosti; Michele Cavo; Michele Baccarani; Giovanni Martinelli
Journal:  Oncotarget       Date:  2016-04-19

6.  Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.

Authors:  Filip Razga; Tomas Jurcek; Ivana Jeziskova; Daniela Zackova; Dana Dvorakova; Marek Borsky; Jiri Mayer; Zdenek Racil
Journal:  Mol Diagn Ther       Date:  2012-06-01       Impact factor: 4.074

7.  Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing.

Authors:  R Kastner; A Zopf; S Preuner; J Pröll; N Niklas; P Foskett; P Valent; T Lion; C Gabriel
Journal:  Eur J Cancer       Date:  2013-12-20       Impact factor: 9.162

8.  Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches.

Authors:  Sandra Preuner; Agnes Barna; Florian Frommlet; Stefan Czurda; Byrgazov Konstantin; Mary Alikian; Katerina Machova Polakova; Tomasz Sacha; Johan Richter; Thomas Lion; Christian Gabriel
Journal:  Int J Mol Sci       Date:  2016-04-29       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.